Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | EORTC 1208 Minitub: a prospective registry of patients with SN positive melanoma

Alexander van Akkooi • 14 Sep 2024
ESMO 2024
Melanoma Skin Cancer
EORTC 1208 Mintub

Alexander Van Akkooi, MD, PhD, Melanoma Institute Australia, Sydney, Australia, gives an overview of the EORTC 1208 Minitub study (NCT01942603), which evaluates outcomes in patients with melanoma, who have a minimal sentinel node (SN) tumor burden managed without complete lymph node dissection. The study reveals that SN tumor burden and AJCC stage are independent prognostic factors, suggesting that minimal SN tumor burden may not necessitate aggressive surgical intervention and could impact future staging systems. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alexander van Akkooi

Melanoma at ESMO 2025: SWOG S1801, NADINA, and more
1:13
Melanoma at ESMO 2025: SWOG S1801, NADINA, and more
Alexander van Akkooi • 18 Oct 2025
Primary analysis of Columbus-AD: encorafenib and binimetinib in high-risk stage II melanoma
1:43
Primary analysis of Columbus-AD: encorafenib and binimetinib in high-risk stage II melanoma
Alexander van Akkooi • 30 May 2025
Importance of minimal sentinel node tumor burden in melanoma staging
0:31
Importance of minimal sentinel node tumor burden in melanoma staging
Alexander van Akkooi • 14 Sep 2024
The evolving role of surgery after neoadjuvant immunotherapy in melanoma
0:50
The evolving role of surgery after neoadjuvant immunotherapy in melanoma
Alexander van Akkooi • 15 Sep 2024

Related Videos

Real-world safety of adoptive cellular therapy with lifileucel in patients with advanced melanoma
2:41
Real-world safety of adoptive cellular therapy with lifileucel in patients with advanced melanoma
Alexandra Haugh • 30 May 2026
A Phase II trial of IO102-IO103 and nivolumab-relatimab in melanoma
1:05
A Phase II trial of IO102-IO103 and nivolumab-relatimab in melanoma
James Smithy • 31 May 2026
Optimal timing of ctDNA dynamics to prognosticate ICI efficacy in melanoma
1:26
Optimal timing of ctDNA dynamics to prognosticate ICI efficacy in melanoma
Vincent Ma • 31 May 2026
Phase Ib/II trial of PHP therapy with nivo/rela in metastatic melanoma and liver metastasis
1:42
Phase Ib/II trial of PHP therapy with nivo/rela in metastatic melanoma and liver metastasis
Vincent Ma • 31 May 2026
The content of VJOncology is intended for healthcare professionals